Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates

• Published in: Vaccine Vol. 30; no. 2; pp. 368 - 377
• Main Authors: Morera, Yanelys, Bequet-Romero, Mónica, Ayala, Marta, Pérez, Pedro Puente, Castro, Jorge, Sánchez, Javier, Alba, José Suárez, Ancízar, Julio, Cosme, Karelia, Gavilondo, Jorge V
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 05.01.2012; Elsevier Limited
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - adverse effects; Allergy and Immunology; animal behavior; Animals; antibodies; antigens; Biological effects; Biotechnology; Breeding of animals; Cancer; Cancer Vaccines - administration & dosage; Cancer Vaccines - adverse effects; Cancer Vaccines - immunology; Cercopithecus aethiops; Cytotoxicity; Disease Models, Animal; Drug dosages; Experiments; Genetic engineering; humans; immune response; Immunization; Immunogenicity; immunoglobulin G; Immunoglobulin G - blood; Immunoglobulin G - immunology; Immunotherapy - adverse effects; Immunotherapy - methods; Laboratory animals; Male; mice; monkeys; Monkeys & apes; Neisseria meningitidis; Neoplasms - therapy; oils; Pancreatic cancer; Primates; Proteins; rabbits; rats; Studies; T-lymphocytes; T-Lymphocytes - immunology; tissue repair; vaccination; Vaccine; Vaccines; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vascular Endothelial Growth Factor A - immunology; vascular endothelial growth factors; VEGF; VSSP; Wound healing; VSSP; Vaccine; VEGF; Cancer
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2011.10.082

Highlights ► CIGB-247 is a cancer therapeutic, based on recombinant modified VEGF as antigen, in combination with powerful adjuvant VSSP. ► We extend the immunogenicity and safety studies of CIGB-247 in non human primates, scaling the antigen dose from 100 μg to 200 and 400 μg/vaccination. ► Higher antigen doses had a positive influence in Ab titer maintenance and boosters achieve maximum Ab VEGF blocking activity, and specific T-cell responses. ► Purified IgG from CIGB-247 immunized monkey produce biological effects in culture cells of endothelial origin. ► Dose escalation was safe and well tolerated.